Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843012 | 0.93 | ABCC2 (0.33) | PARP1 | |
| SCHEMBL2849020 | 0.93 | ABCC2 (0.33) | PARP1 | |
| SCHEMBL13001881 | 0.93 | ABCC2 (0.33) | PARP1 | |
| SCHEMBL2843017 | 0.93 | ABCC2 (0.33) | PARP1 | |
| SCHEMBL2850800 | 0.91 | ABCC2 (0.33) | PARP1 | |
| SCHEMBL2850805 | 0.91 | ABCC2 (0.33) | PARP1 | |
| SCHEMBL13787612 | 0.91 | — | — | |
| SCHEMBL2853121 | 0.90 | ABCC2 (0.33) | PARP1 | |
| SCHEMBL2853124 | 0.90 | ABCC2 (0.33) | PARP1 | |
| SCHEMBL2853573 | 0.88 | PARP1 (0.35) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213595-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2009084614-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213595-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | PARP1 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.